The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non-small cell lung cancer

被引：0
作者：
Koemuercueoglu, B. [1 ]
Aydogan, H. [1 ]
Tekguel, S. [1 ]
Cecen, E. [1 ]
Yalniz, E. [1 ]
Oezden, E. Pala [1 ]
机构：
[1] Izmir Res & Training Hosp Chest Dis & Surg, Izmir, Turkey
来源：
LUNG CANCER | 2006年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 50 条
[21]   Analysis of the costs of bevacizumab plus cisplatin and gemcitabine versus cetuximab plus vinorelbine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) in France: Results from a cost modelling study [J].
Chouaid, C. ;
Vergnenegre, A. ;
Florentin, V. ;
Walzer, S. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[22]   Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer [J].
Ramsey, SD ;
Moinpour, CM ;
Lovato, LC ;
Crowley, JJ ;
Grevstad, P ;
Presant, CA ;
Rivkin, SE ;
Kelly, K ;
Gandara, DR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (04) :291-297
[23]   THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS [J].
Nuijten, M. J. ;
Holmberg, C. ;
Walzer, S. .
VALUE IN HEALTH, 2009, 12 (07) :A272-A272
[24]   Prospective randomized phase III trial of triplet chemotherapy with paclitaxel plus gemcitabine plus cisplatin compared to standard doublet chemotherapy with vinorelbine plus cisplatin in advanced non-small cell lung cancer [J].
Sorensen, J. ;
Hansen, O. ;
Vilmar, A. ;
Frank, H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[25]   Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [J].
Scagliotti, Giorgio ;
Purvish, Parikh ;
von Pawel, Joachim ;
Biesma, Bonna ;
Vansteenkiste, Johan ;
Manegold, Christian ;
Simms, Lorinda ;
Posther, Sugarman Katherine ;
Obasaju, Coleman ;
Blatter, Johannes .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :S306-S306
[26]   Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [J].
Manegold, C. ;
Digumarti, R. ;
Zukin, M. ;
de Marinis, F. ;
Mellerngaard, A. ;
Gandara, D. ;
Simms, L. ;
Kaiser, C. ;
Blatter, J. ;
Gatzemeier, U. .
EJC SUPPLEMENTS, 2007, 5 (06) :9-9
[27]   Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer [J].
Yun Fan ;
Neng-ming Lin ;
Sheng-lin Ma ;
Lü-hong Luo ;
Luo Fang ;
Zhi-yu Huang ;
Hai-feng Yu ;
Feng-qin Wu .
Acta Pharmacologica Sinica, 2010, 31 :746-752
[28]   Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer [J].
Fan, Yun ;
Lin, Neng-ming ;
Ma, Sheng-lin ;
Luo, Lue-hong ;
Fang, Luo ;
Huang, Zhi-yu ;
Yu, Hai-feng ;
Wu, Feng-qin .
ACTA PHARMACOLOGICA SINICA, 2010, 31 (06) :746-752
[29]   Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study [J].
Orlandi-Jorquera, L ;
Orlandi, F ;
Galaz, P ;
Gamargo, C ;
Salman, P ;
Yanez, M .
ANNALS OF ONCOLOGY, 1998, 9 :101-101
[30]   Quality of life in non-small cell lung cancer patients receiving gemcitabine (Gemzar®) plus cisplatin or etoposide plus cisplatin [J].
Rosell, R ;
Cardenal, F ;
Montes, A ;
Artal, A ;
Carrato, A ;
Lomas, M ;
Alberola, V ;
Barnetto, I ;
Massuti, B ;
Liepa, AM .
ANNALS OF ONCOLOGY, 1998, 9 :84-84
12345